3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
2
Expanded_access
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Interventions
gallium 68 PSMA-11
4
Magnetic Resonance Spectroscopy
4
Abiraterone Acetate
3
carbon-11 acetate
2
Prednisone
2
Prednisolone
2
Axitinib
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
zenocutuzumab
1
ulixertinib
1
trametinib
1
tempol
1
tazemetostat
1
talazoparib
1
radium Ra 223 dichloride
1
pegilodecakin
1
omburtamab I-131
1
niraparib
1
neratinib
1
motexafin gadolinium
1
enfortumab vedotin
1
dodecyl maltoside
1
bicalutamide
1
bemarituzumab
1
balstilimab
1
atezolizumab
1
apalutamide
1
TEMPOL-H
1
Suspensions
1
Sunitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
bemarituzumab
×
Genitourinary
×
Clear all
NCT03801278
2021-12-13
FPA144
Five Prime Therapeutics, Inc.
No longer available